A5000585816- Gestational Diabetes Research and Management
- Pancreatic function and diabetes
- Diabetes Treatment and Management
- Maternal and fetal healthcare
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Cardiovascular Health and Disease Prevention
- COVID-19 Impact on Reproduction
- Prenatal Substance Exposure Effects
- Food Security and Health in Diverse Populations
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes and associated disorders
- Metabolism, Diabetes, and Cancer
University of British Columbia
2014-2023
Fraser Health
2020-2023
Surrey Memorial Hospital
2023
North Manchester General Hospital
2013
Injectable semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that was previously shown to be superior liraglutide and dulaglutide in head-to-head comparisons GLP-1 RA-naïve individuals. It hypothesized will cause further reductions glycated hemoglobin A1c (HbA1c) weight type 2 diabetes mellitus (T2DM) patients treated with or dulaglutide. The REALISE-DM study provides the first real-world evidence of effectiveness tolerability switching from another RA. This retrospective...
The response to glucagon-like peptide 1 receptor agonist treatment may be influenced by endogenous β-cell function. We investigated whether urinary C-peptide creatinine ratio assessed before or during liraglutide was associated with response.A single, outpatient urine sample for collected 2 h after the largest meal of day among two separate groups: (1) subjects initiating (0.6 → 1.2 mg daily) (2) already treated 20-32 weeks. associations between pretreatment and on-treatment HbA1c change at...
At the start of COVID-19 pandemic, Jim Pattison Diabetes and Pregnancy (JP DAP) clinic quickly switched from in-person to virtual care for patients with gestational diabetes (GDM) reduce risk viral transmission. Poor glycaemic control in pregnancies increases maternal-fetal complications thus women GDM require education, frequent follow-up treatment these risks. Delays could potentially result increased complications. We conducted a prospective, single-centre quality improvement (QI) study...
<h3>Background</h3> Surrey Memorial Hospital (SMH) serves one of the fastest growing cities in Canada. 12% Surrey's population has diabetes compared to 8% all British Columbia with 3,455 new cases diagnosed each year. 67% patients discharged from SMH have and a longer length stay (LOS). The lack timely, effective insulin teaching discharge planning was found be barriers timely discharges. <h3>Objectives</h3> 1. To optimize process overcome co-creating safe discharge. 2. evaluate impact...